Can response to palliative treatment with radiopharmaceuticals be further enhanced?

Hellenic Journal of Nuclear Medicine

Volumn 12, Issue 2, 2009, Pages

  Zafeirakis, Athanasios ^a  

^a 401 Athens Army Hospital   (Greece)

Author keywords

Bone pain palliation; Radionuclide treatment; Rhenium 186; Rhenium 188; Samarium 153; Strontium 89

Indexed keywords

ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CISPLATIN; DOCETAXEL; DOXORUBICIN; ESTRAMUSTINE; ETIDRONIC ACID RE 186; ETIDRONIC ACID RE 188; GEMCITABINE; LEXIDRONAM SAMARIUM SM 153; OPIATE; PHOSPHONIC ACID DERIVATIVE; PLACEBO; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; RHENIUM 188; SAMARIUM 153; STRONTIUM 89; UNCLASSIFIED DRUG; VINBLASTINE; ZOLEDRONIC ACID;

ABSENCE OF SIDE EFFECTS; ADD ON THERAPY; ANALGESIA; ANOREXIA; BLOOD TOXICITY; BONE DISEASE; BONE MARROW TOXICITY; BONE METASTASIS; BONE PAIN; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CYTOPENIA; DISEASE COURSE; DRUG EFFICACY; DRUG MEGADOSE; EXTERNAL BEAM RADIOTHERAPY; HUMAN; ISOTOPE LABELING; LOW DRUG DOSE; OSTEOSARCOMA; RADIATION DOSE DISTRIBUTION; RADIATION RESPONSE; REPEATED DRUG DOSE; REVIEW; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT;

HUMANS; NEOPLASMS; PAIN; PALLIATIVE CARE; RADIOPHARMACEUTICALS; RADIOTHERAPY, ADJUVANT;

EID: 69249199791     PISSN: 11081430     EISSN: 17905427     Source Type: Journal    
DOI: None     Document Type: Review

References (77)

1. Campa JA, Payne R. The management of intractable bone pain: a clinician's perspective. Semin Nucl Med 1992; 22: 3-10.
2. McEwan AJB. Unsealed source therapy of painful bone metastases: an update. Semin Nucl Med 1997; 27: 165-182. (Pubitemid 27194761)
3. Lewington VJ. Targeted radionuclide treatment for bone metastases. Eur J Nucl Med 1993; 20: 66-74.
4. 186Re-HEDP to patients with bone metastases. J Nucl Med 1991; 32: 1082.
5. Silberstein EB. Teletherapy and RF Therapy of Painful Bone Metastases. Semin Nucl Med 2005; 35: 152-158.
6. Valdés Olmos RA, Hoefnagel CA. Radionuclide treatment in oncology: the dawning of its concomitant use with other modalities? Eur J Nucl Med Mol Imaging 2004; 31: 929-931.
7. McEwan AJB. Radioisotope therapy and clinical trial design: the need for consensus and innovation. J Nucl Med 2002; 43: 87-88.
8. 186Re-HEDP for metastatic bone pain in breast cancer patients. Eur J Nucl Med Mol Imaging 2004; 31: S162-S170.
9. Humm JL. Dosimetric aspects of radiolabeled antibodies for tumor therapy. J Nucl Med 1986; 27: 1490-1497. (Pubitemid 17028574)
10. Graham CW, Lynch JH, Djakiew D. Distribution of nerve growth factor-like protein and nerve growth factor receptor in human benign prostatic hyperplasia and prostatic adenocarcinoma. J Urol 1992; 147: 1444-1447.
11. Samaratunga RC, Thomas SR, Hinnefeld JD et al. A Monte Carlo simulation model for radiation dose to metastatic skeletal tumor from rhenium-186 (Sn)-HEDP. J Nucl Med 1995; 36: 336-350.
12. 186Re-HEDP treatment of skeletal metastases from prostate cancer. Eur J Nucl Med Mol Imaging 2003; 30: 1114-1124.
13. 186Re-HEDP therapy depends upon the number of metastases. Radiology 2001; 221(P): 344.
14. McCready VR, O'Sullivan J, Buffa F et al. The relationship between skeletal metastatic load and therapeutic activity requirement in prostate cancer. Eur J Nucl Med 2001; 28: 1054.
15. 186Re-HEDP with autologous peripheral blood stem cell transplant in progressive hormone-refractory prostate cancer metastatic to bone. Eur J Nucl Med Mol Imaging 2006; 33: 1055-1061.
16. Soloway MS, Hardeman SW, Hickey D, et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 1988; 61: 195-200. (Pubitemid 18023133)
17. Knudson G, Grinis G, Lopez-Majano V, et al. Bone scan as a stratification variable in advanced prostate cancer. Cancer 1991; 68: 316-320.
18. Pantelides ML, Bowman SP, George NJ. Levels of prostate specific antigen that predict skeletal spread in prostate cancer. Br J Urol 1992; 70: 299-303.
19. Miller PD, Eardley I, Kirby RS. Prostate specific antigen and bone scan correlation in the staging and monitoring of patients with prostatic cancer. Br J Urol 1992; 70: 295-298.
20. Ernst DS, Hanson J, Venner PM. Analysis of prognostic factors in men with metastatic prostate cancer. J Urol 1991; 146: 372-376.
21. Akimoto S, Furuya Y, Akakura K, et al. Inability of Bone Turnover Marker as a Strong Prognostic Indicator in Prostate Cancer Patients With Bone Metastasis: Comparison With the Extent of Disease (EOD) Grade. The Prostate 1999; 38: 28-34. (Pubitemid 29011014)
22. Windsor PM. Predictors of response to strontium-89 (Metastron) in skeletal metastases from prostate cancer: report of a single centre's 10-year experience. Clin Oncol (R Coll Radiol) 2001; 13: 219-227.
23. Crawford E, Eisenberger M, McLeod K. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989; 321: 419-424. (Pubitemid 19211484)
24. Yamashita K, Denno K, Ueda T, et al. Prognostic significance of bone metastases in patients with metastatic prostate cancer. Cancer 1993; 71: 1297-1302. (Pubitemid 23054922)
25. Jinnouchi S, McCready VR, Al-Nahhas AM. A technique for quantitation of changes in serial bone scintigrams in carcinoma of the prostate. J Nucl Med 1996; 37: 180.
26. de Klerk JMH, Zonnenberg BA, van het Schip AD et al. Dose escalation study of rhenium-186 hydroxyethylidene diphosphonate in patients with metastatic prostate cancer. Eur J Nucl Med 1994; 21: 1114-1120.
27. Kraeber-Bodéré F, Campion L, Rousseau C et al. Treatment of bone metastases of prostate cancer with strontium-89 chloride: efficacy in relation to the degree of bone involvement. Eur J Nucl Med 2000; 27: 1487-1493. (Pubitemid 30780243)
28. Berna L, Carrio I, Alonso C et al. Bone pain palliation with strontium-89 in breast cancer patients with bone metastases and refractory bone pain. Eur J Nucl Med 1995; 22: 1101-1104.
29. Laing AH, Ackery DM, Bayly RJ et al. Strontium-89 chloride for pain palliation in prostatic skeletal malignancy. Br J Radiol 1991; 64: 816-822.
30. Silberstein EB. Advances in Our Understanding of the Treatment of Painful Bone Metastases. J Nucl Med 2000; 41: 655-657.
31. Quilty PM, Kirk D, Bolger JJ et al. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol 1994; 31: 33-40.
32. 89Sr) palliation in patients with advanced prostate cancer metastatic to bone. Eur J Cancer 1991; 27: 954-958.
33. McCready VR, O'Sullivan JM. Future directions for unsealed source radionuclide treatment for bone metastases. Eur J Nucl Med 2002; 29: 1271-1275.
34. Hillegonds DJ, Franklin S, Shelton DK et al. The management of painful bone metastases with an emphasis on radionuclide treatment. J Natl Med Assoc 2007; 99: 785-794. (Pubitemid 47076147)
35. Lewington VJ. Bone-Seeking Radionuclides for Therapy. J Nucl Med 2005; 46: 38S-47S.
36. Turner JH, Claringbold PG. A phase II study of treatment of painful multifocal skeletal metastases with single and repeated dose samarium-153 ethylenediaminetetramethylene phosphate. Eur J Cancer 1999; 27: 1084-1086.
37. Palmedo H, Manka-Waluch A, Albers P et al. Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: randomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate. J Clin Oncol 2003; 21: 2869-2875. (Pubitemid 46621835)
38. Graham MC, Scher HI, Liu GB et al. Rhenium-186-labeled Hydroxyethylidene Diphosphonate Dosimetry and Dosing Guidelines for the Palliation of Skeletal Metastases from Androgen-independent Prostate Cancer. Clinical Cancer Research 1999; 5: 1307-1318.
39. Fuster D, Herranz R, Alcover J et al. Treatment of metastatic bone pain with repeated doses of strontium-89 in patients with prostate neoplasm. Rev Exp Nucl Med 2000; 19: 270-274.
40. Kasalicky J, Krajska V. The effect of repeated strontium-89 chloride therapy on bone pain palliation in patients with skeletal cancer metastases. Eur J Nucl Med 1998; 25: 1362-1367. (Pubitemid 28464109)
41. 153Sm-EDTMP therapy includes pain palliation and lesion regression/stabilization (abstract). Eur J Nucl Med 2001; 28: 1198.
42. 153Sm-EDTMP in bone metastasis from different cancers (abstract). Eur J Nucl Med 2001; 28: 1054.
43. Paszkowski AL, Hewitt DJ, Taylor A. Disseminated intravascular coagulation in a patient treated with strontium-89 for metastatic carcinoma of the prostate. Clin Nucl Med 1999; 24: 852-854.
44. Dafermou A, Colamussi P, Giganti M, et al. A multicentre observational study of radionuclide treatment in patients with painful bone metastases of prostate cancer. Eur J Nucl Med 2001; 28: 788-798. (Pubitemid 32662540)
45. Anderson PM, Wiseman GA, Dispenzieri A et al. High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J Clin Oncol 2002; 20: 189-196. (Pubitemid 34032611)
46. Palmedo H, Guhlke S, Bender H et al. Dose escalation study with rhenium-188 HEDP in prostate cancer patients with osseous metastases. Eur J Nucl Med 2000; 27: 123-130. (Pubitemid 30102016)
47. Palmedo H, Bucerius J. Radionuclide treatment in oncology: repeated administrations of high dose rate radiopharmaceuticals. Eur J Nucl Med Mol Imaging 2004; 31: 1556. (Pubitemid 39592777)
48. 90Y. Radiother Oncol 1991; 21: 91-99.
49. O'Donoghue JA, Bardies M, Wheldon TE. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med 1995; 36: 1902-1909.
50. Karagiannis TC. Antibody-based cancer treatment with ultra-short range Auger electron-emitting radionuclides: dual receptor and DNA targeting strategies. Hell J Nucl Med 2007; 10: 155-159.
51. Karagiannis TC. Comparison of different classes of radionuclides for potential use in radioimmunotherapy. Hell J Nucl Med 2007; 10: 82-88.
52. Porter AT, McEwan AJB, Powe JE et al. Results of a randomized phase-III trial to evaluate the efficacy of Strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol BiolPhys 1993; 25: 805-813.
53. Smeland S, Erikstein B, Aas M et al. Role of strontium-89 as adjuvant to palliative external beam radiotherapy is questionable: results of a double-blind randomized study. Int J Radiat Oncol Biol Phys 2003; 56: 1397-1404. (Pubitemid 36842893)
54. Pecherstorfer M, Schilling T, Janisch S et al. Effect of clodronate treatment on bone scintigraphy in metastatic breast cancer. J Nucl Med 1993; 34: 1039-1044. (Pubitemid 23191316)
55. 99mTc-methylene diphosphonate bone scanning. J Nucl Med 2001; 42: 1359-1363. (Pubitemid 32852611)
56. 153Sm-EDTMP. Clin Nucl Med 2002; 27: 427-430. (Pubitemid 34546817)
57. 186Re-HEDP in women with breast cancer and disseminated bone metastases. Turk J Nucl Med 2004; 13: 69.
58. 188Re-HEDP and pamidronate in breast cancer with bone metastasis. Zhonghua Zhong Liu Za Zhi 2005; 27: 180-182.
59. 89Sr and zoledronic acid in patients with painful bone metastases. Bone 2006; 39: 35-41. (Pubitemid 43842022)
60. 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases Eur J Nucl Med Mol Imaging 2008; 35: 756-765.
61. Wang RF, Zhang CL, Zhu SL et al. Comparative study of samarium-153-ethylenediaminetetramethylene phosphonic acid with pamidronate disodium in the treatment of patients with painful metastatic bone cancer. Med Princ Pract 2003; 12: 97-101.
62. Berry S, Waldron T, Winquist E, Lukka H. The use of bisphosphonates in men with hormone-refractory prostate cancer: a systematic review of randomized trials. Can J Urol 2006; 13: 3180-3188.
63. Amato RJ, Hernandez-McClain J, Henary H. Bone-targeted therapy: phase II study of strontium-89 in combination with alternating weekly chemohormonal therapies for patients with advanced androgen-independent prostate cancer. Am J Clin Oncol 2008; 31: 532-538.
64. Logothetis C, Tu S, Navone N. Targeting prostate cancer bone metastases. Cancer 2003; 97: 785-788. (Pubitemid 36125813)
65. Tu S, Millikan RE, Mengistu B et al. Bone-targeted therapy for advanced androgen independent carcinoma of the prostate: a randomised phase II trial. Lancet 2001; 367: 336-341. (Pubitemid 32128538)
66. Tu SM, Kim J, Pagliaro LC et al. Therapy tolerance in selected patients with androgen-independent prostate cancer following strontium-89 combined with chemotherapy. J Clin Oncol 2005; 23: 7904-7910. (Pubitemid 46657389)
67. Mertens WC, Porter AT, Reid RH, Powe JE. Strontium-89 and low-dose infusion cisplatin for patients with hormone refractory prostate carcinoma metastatic to bone: a preliminary report. J Nucl Med 1992; 33: 1437-1443.
68. 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial. J Nucl Med 2002; 43: 79-86. (Pubitemid 34101193)
69. Akerley W, Butera J, Wehbe T et al. A multiinstitutional, concurrent chemoradiation trial of strontium-89, estramustine, and vinblastine for hormone refractory prostate carcinoma involving bone. Cancer 2002; 94: 1654-1660. (Pubitemid 34241101)
70. Pagliaro LC, Delpassand ES, Williams D et al. A phase I/II study of strontium-89 combined with gemcitabine in the treatment of patients with androgen independent prostate carcinoma and bone metastases. Cancer 2003; 12: 2988-2994. (Pubitemid 36676252)
71. Widmark A, Linne T, Modig H, Johansson L. Optimizing the time of co-administration of docetaxel and samarium-153 for advanced androgen independent carcinoma of the prostate (abstr.). Proc Am Soc Clin Oncol 2003; 22: 433.
72. 153Sm- lexidronam and docetaxel for the treatment of patients with hormone-refractory prostate cancer: first experience. Cancer Biother Radiopharm 2008; 23: 609-618.
73. Laplanche A, Beuzeboc P, Lumbroso J et al. A phase II trial of docetaxel and samarium in patients with bone metastases from castration-refractory prostate cancer (CRPC) and a response or stabilization after induction docetaxel-estramustine (abstr.). Proc Am Soc Clin Oncol 2006; 24: 4608.
74. 153Sm-EDTMP in myeloablative dosage followed by a second autotransplantation in patients with relapsed multiple myeloma (abstr.). Haematologica 2004; 89: ECR36.
75. 153Sm-EDTMP skeletally targeted radiotherapy in an orthotopic model of multiple myeloma. Blood 2006; 107: 4063-4070. (Pubitemid 43726815)
76. Anderson PM, Wiseman GA, Erlandson L et al. Gemcitabine radiosensitization after high dose samarium for osteoblastic osteosarcoma. Clin Cancer Res 2005; 11: 6895-6900.
77. 153Sm-EDTMP and meiphalan as a conditioning regimen for sec- ondary acute myelogenous leukemia. Pediatr Transplantation 2005; 9: 122-126. (Pubitemid 40238977)